EUCTR2019-000661-20-LT进行中（未招募）1 期
Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial. - ICO
Vilnius University Hospital Santaros klinikos0 个研究点目标入组 150 人开始时间: 2019年4月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Chemotherapy with anthracyclines;
- •Age 18-80 years;
- •Heart rate = 70 times per minute;
- •Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Contraindications for ivabradine administration;
- •heart rate <70 times per minute;
- •Incapability to complete informed consent;
- •Severe valve disease;
- •Left ventricle ejection fraction = 30 proc.;
- •Poor echogenicity.
研究者
相似试验
Unknown
不适用
Ivabradine to Prevent Anthracycline-induced CardiotoxicityNeoplasmsCardiotoxicityHeart FailureChemotherapy EffectOncologyNCT03650205University of Sao Paulo160
进行中（未招募）
不适用
Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies.EUCTR2012-002248-26-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
不适用
Primary Prevention of Anthracycline-induced Cardiotoxicity with L-Carnitine in patients with breast Cancer (PPACC): pilot studyBreast CancerCancerISRCTN32332192niversity of Ottawa Heart Institute (Institut de cardiologie de l'Université d'Ottawa) (Canada)144
Unknown
3 期
Ivabradine to Prevent Anthracycline-induced CardiotoxicityPatients With CancerNCT04030546Vilnius University128
已完成
3 期
Ivabradine in controlling elevated heart rate among sick patientsCTRI/2010/091/002969Fluid Research Grant Christian Medical CollegeVellore Tamilnadu100